跳至主要内容
临床试验/NCT06731933
NCT06731933招募中2 期

Impact of Collagen VII Gene Therapy on Squamous Cell Carcinoma Recurrence in Recessive Dystrophic Epidermolysis Bullosa Skin

Stanford University2 个研究点 分布在 2 个国家目标入组 16 人开始时间: 2025年3月28日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
招募中
入组人数
16
试验地点
2
主要终点
Recurrence rate of Squamous Cell Carcinoma

研究概览

简要总结

The study objective is to see if BVEC induced C7 expression in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin following Squamous cell carcinoma (SCC) excision will normalize the invasive tumor microenvironment and reduce tumor recurrence.

Prevention of SCC's in the RDEB subjects will increase their life span.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Prevention
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of generalized Recessive dystrophic epidermolysis bullosa (RDEB) demonstrated by COL7A1 mutations
  • Presence of biopsy proven squamous cell carcinoma (SCC)
  • Ability to understand and the willingness to provide written informed consent.
  • US based participants are willing to use beremagene geperpavec (BVEC)
  • Subject is 18 years or older
  • participant willingness to use an effective method of contraception

排除标准

  • Inability to travel to site for study visit
  • Subject is pregnant
  • Subject has Metastatic SCC's or is on any current systemic treatment for SCC.

研究组 & 干预措施

Treatment with BVEC

Active Comparator

干预措施: BVEC (Drug)

No treatment with BVEC

No Intervention

结局指标

主要结局

Recurrence rate of Squamous Cell Carcinoma

时间窗: 2 years

The outcome measure is recurrence rate of SCC following BVEC application at each SCC lesion

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验